Company Filing History:
Years Active: 2018-2021
Title: Tetsuo Yamagishi: Innovator in Cancer Treatment
Introduction
Tetsuo Yamagishi is a notable inventor based in Macquarie Park, Australia. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic antibodies.
Latest Patents
Yamagishi holds 2 patents related to Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B. These antibodies specifically bind to CD38 and are designed to inhibit the proliferation of cancerous cells that express both CD38 and the receptor for IFN-alpha2b. The constructs comprising these antibodies fused to attenuated interferon alpha-2B proteins may also induce apoptosis in such cells. This innovative approach serves as a potential basis for treating underlying cancers.
Career Highlights
Yamagishi is currently employed at Teva Pharmaceuticals Australia Pty Ltd, where he continues to advance his research in the field of oncology. His work focuses on developing novel therapeutic strategies to combat cancer.
Collaborations
Some of his notable coworkers include Adam Clarke and Matthew Pollard, who contribute to the collaborative efforts in research and development at Teva Pharmaceuticals.
Conclusion
Tetsuo Yamagishi's work in developing Anti-CD38 antibodies and their applications in cancer treatment highlights his significant role in the field of medical innovation. His contributions are paving the way for new therapeutic options in oncology.